Wullich B, Füssel S, Grobholz R
Klinik für Urologie und Kinderurologie, Universitätsklinikum des Saarlandes, Kirrberger Strasse, Geb. 6, 66421 Homburg/Saar, Germany.
Urologe A. 2007 Jun;46(6):675-82; quiz 682-4. doi: 10.1007/s00120-007-1359-9.
As individual risk assessment mainly depends on the correct prediction of the tumor's biological behavior, primary diagnosis plays a key role in the clinical management of prostate cancer patients. Prostate core needle biopsy, as a primary diagnostic tool, should not only confirm clinical suspicion but also supply the urologist with information which is necessary for risk-adapted therapy. The experience and competence of both the urologist and the pathologist are crucial for the quality of prostate core needle biopsy diagnosis. Optimized handling and submission of prostate core needle biopsy specimens by the urologist to the pathologist are of outstanding importance for improving the number of cancer cases detected. Increasing availability of molecular markers leads to the necessity of developing new tissue sampling procedures which allow prostate core needle biopsy specimens to be simultaneously studied histologically and by molecular approaches.
由于个体风险评估主要依赖于对肿瘤生物学行为的正确预测，因此初诊在前列腺癌患者的临床管理中起着关键作用。前列腺穿刺活检作为一种主要的诊断工具，不仅应证实临床怀疑，还应为泌尿外科医生提供风险适应性治疗所需的信息。泌尿外科医生和病理科医生的经验和能力对于前列腺穿刺活检诊断的质量至关重要。泌尿外科医生对前列腺穿刺活检标本进行优化处理并提交给病理科医生，对于提高癌症病例的检出数量极为重要。分子标志物的可用性不断增加，导致有必要开发新的组织采样程序，以便对前列腺穿刺活检标本同时进行组织学和分子学研究。
